Alyeska Investment Group, L.P. Phathom Pharmaceuticals, Inc. Transaction History
Alyeska Investment Group, L.P.
- $18 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
143Shares Held
74.8MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$70.3 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$51.9 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$49.1 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$28.5 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$24.3 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $272M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...